Toggle Main Menu Toggle Search

Open Access padlockePrints

RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia—an international Delphi consensus

Lookup NU author(s): Professor John O'Brien, Professor John-Paul TaylorORCiD, Professor David BrooksORCiD, Professor Ian McKeith, Professor Alison Yarnall



This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


© 2022, The Author(s).Drug repositioning and repurposing has proved useful in identifying new treatments for many diseases, which can then rapidly be brought into clinical practice. Currently, there are few effective pharmacological treatments for Lewy body dementia (which includes both dementia with Lewy bodies and Parkinson’s disease dementia) apart from cholinesterase inhibitors. We reviewed several promising compounds that might potentially be disease-modifying agents for Lewy body dementia and then undertook an International Delphi consensus study to prioritise compounds. We identified ambroxol as the top ranked agent for repurposing and identified a further six agents from the classes of tyrosine kinase inhibitors, GLP-1 receptor agonists, and angiotensin receptor blockers that were rated by the majority of our expert panel as justifying a clinical trial. It would now be timely to take forward all these compounds to Phase II or III clinical trials in Lewy body dementia.

Publication metadata

Author(s): O'Brien JT, Chouliaras L, Sultana J, Taylor J-P, Ballard C, Aarsland D, Blanc F, Boeve B, Brooks DJ, Chaudhuri KR, Cummings J, Feldman HH, Flicker L, Galvin JE, Grosset DG, Ikeda M, Kohlhaas S, Lawlor B, Lemstra AW, Leroi I, Londos E, Leverenz JB, Lewis S, McKeith I, Mills R, Oakley R, Richardson J, Sabbagh M, Skidmore J, Svennigsson P, Tiraboschi P, Weintraub D, Walker Z, Watson R, Weil RS, Williams-Gray CH, Yarnall A

Publication type: Review

Publication status: Published

Journal: Alzheimer's Research and Therapy

Year: 2022

Volume: 14

Issue: 1

Print publication date: 01/12/2022

Online publication date: 11/11/2022

Acceptance date: 17/10/2022

ISSN (electronic): 1758-9193

Publisher: BioMed Central Ltd


DOI: 10.1186/s13195-022-01103-7

PubMed id: 36369100